Arzneimittelforschung 2007; 57(4): 227-231
DOI: 10.1055/s-0031-1296609
Antibiotics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Comparative Pharmacokinetics of Two Tablet Formulations of Amoxicillin: Bioequivalence Assessment

Reinhard Sailer
1  Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany
,
Peter Arnold
1  Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany
,
Aydin Erenmemişoğlu
2  DEKAM-IKU,Good Clinical Practices Center, Erciyes University, Medical School, Kayseri, Turkey
,
Wolfgang Martin
1  Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany
,
Uygur Tamur
3  DEVA Holding A.Ş, 4. Levent, Istanbul, Turkey
,
Ilker Kanzik
4  IDE Pharmaceutical Consulting, Kavaklidere, Ankara, Turkey
5  Gazi University Faculty of Pharmacy, Department of Pharmacology, Etiler Ankara, Turkey
,
A.Atilla Hincal
4  IDE Pharmaceutical Consulting, Kavaklidere, Ankara, Turkey
6  Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Sihhiye, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

Publication Date:
21 December 2011 (online)

Abstract

The aim of the present study was to compare the bioavailability of amoxicillin (CAS 26787-78-0) from two different amoxicillin tablets (Demoksil© 1 g tablet as test preparation and 1 g tablet of the originator product as reference preparation). The study was conducted according to an open-label, randomised two-period cross-over design with a wash-out phase of 4-7 days.

Blood samples for pharmacokinetic profiling were taken up to 10 h post-dose, and amoxicillin plasma concentrations were determined with a validated LC-MS/ MS method.

Maximum plasma concentrations (Cmax) of 13,296.4 ng/ml (test) and 12,797.7 ng/ml (reference) were achieved. Areas under the plasma concentration-time curve (AUC0→∞)of 39,556.7 ng · h/ml (test) and 38,599.1 ng · h/ml (reference) were calculated. The median tmax was 1.62 h (test) and 1.54 h (reference). Plasma elimination half-lives (t1/2) of 1.64 h (test) and 1.65 h (reference) were determined. Both primary target parameters, AUC0→∞ and Cmax were tested parametri-cally by analysis of variance (ANOVA) and the 90% confidence intervals were between 96.76%-108.46% (AUC0→∞)and 97.80%-111.98% (Cmax). Bioequivalence between test and reference preparation was demonstrated since for both parameters, AUC and Cmax the 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80%-125%.